Biora Therapeutics/BIOR

$1.42

-7.79%
-
1D1W1MYTD1YMAX

About Biora Therapeutics

Biora Therapeutics, Inc. is a biotechnology company, which is focused on creating smart pills designed for targeted drug delivery to the gastrointestinal (GI) tract, and needle-free delivery of biotherapeutics. The Company's therapeutics pipeline includes two therapeutic delivery platforms: NAVICAP and BIOJET. NAVICAP is a targeted oral delivery platform of therapeutics to the site of disease in the GI tract, designed to improve outcomes for patients with inflammatory bowel disease (IBD). The NAVICAP drug delivery device is an investigational, clinical-stage, single-use ingestible device approximately the size of a fish oil capsule. BIOJET is a systemic oral delivery platform of biotherapeutics designed to replace injection with needle-free, oral delivery of molecules for better management of chronic diseases. The Company's targeted therapeutics pipeline programs include NAVICAP, BT-600 and BT-001. Its systemic therapeutics pipeline programs include BIOJET, BT-200 and BT-002.

Ticker

BIOR

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Aditya Mohanty

Employees

54

Headquarters

San diego, United States

BIOR Metrics

BasicAdvanced
$24.89M
Market cap
-
P/E ratio
-$9.59
EPS
1.01
Beta
-
Dividend rate

What the Analysts think about BIOR

Analyst Ratings

Majority rating from 1 analysts.
Buy

Price Targets

Average projection from 2 analysts.
1,857.75% upside
High $50.00
Low $5.60
$1.42
Current price
$27.80
Average price target

BIOR Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$0
-
Net income
$-73.4M
312.36%
Profit margin
0%
-

BIOR Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 428.65%
QuarterlyAnnual
Q4 22
Q2 23
Q3 23
Q4 23
Actual
-$1.64
-$1.47
-$4.89
-
Expected
-$1.45
-$1.60
-$0.93
-$0.60
Surprise
13.49%
-8.13%
428.65%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Biora Therapeutics stock

Buy or sell Biora Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing